ARCHIVES OF OSTEOPOROSIS, cilt.17, sa.1, 2022 (SCI-Expanded)
Denosumab leads to improvements in BMD levels and is a well-tolerated agent according to results of randomized controlled studies but results in real-life setting are important to evaluate drug adherence and real-life efficiency. In this study, we present the results of 305 patients that were treated with denosumab in our clinic.